Clinical Trials Logo

Clinical Trial Summary

Randomized, controlled, prospective trial, including ICU patients with Sepsis or septic Shock, at the early phase.

patients will be randomized in 2 groups regarding the hemodynamic management and catecholamin doses:

- Group 1: standard hemodynamic goals and catecholamin infusion to achieve: mean arterial pressure > or equal to 65 mmHg and diastolic arterial pressure > ou equal to 50 mmHg within the first 60 minutes.

- Group 2: personalized hemodynamic goals and catecholamin infusion until normal transcranial doppler: IP<1,2.


Clinical Trial Description

Randomized, controlled, prospective trial, including ICU patients with Sepsis or septic Shock, at the early phase.

patients will be randomized in 2 groups regarding the hemodynamic management and catecholamin doses:

- Group 1: standard hemodynamic goals and cathecolamin infusion to achieve: mean arterial pressure > or equal to 65 mmHg and diastolic arterial pressure > ou equal to 50 mmHg within the first 60 minutes.

- Group 2: personalized hemodynamic goals and cathecolamin infusion until normal transcranial doppler: IP<1,2.

For the 2 groups, standard management including: microbiological sampling, early broad spectrum anti infective therapy, fluid management and decreasing of blood lactate levels, will be aimed within the first 60 minutes.

For the Group 2 patients: personalized hemodynamic management will be maintained during 72 hours. ;


Study Design


Related Conditions & MeSH terms

  • Shock
  • Shock, Septic
  • Trans Cranial Doppler Ultrasonography in Heamodynamic Optimisation in Septic Shock

NCT number NCT04398069
Study type Interventional
Source Mongi Slim Hospital
Contact Mhamed Sami Mebazaa, professor
Phone 0021622252589
Email msmebazaa@gmail.com
Status Recruiting
Phase N/A
Start date January 2, 2020
Completion date October 30, 2020